Septerna, Inc. (SEPN) Stock Price & Analysis

Septerna, Inc. (SEPN) closed at USD 45.23 on Thursday, October 29, 2026, up 2.21% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 44.25; the Oct 29, 2026 session ranged USD 43.74–45.6 on volume of 200,615 shares. Market capitalization is $2.11B, with a 52-week range of USD 17.55–51.1 (NGM). Source: Nexqual, retrieved October 29, 2026 at 22:13 UTC.

Also available as compact Markdown for AI agents: nexqual.com/SEPN.md

Key facts (SEPN)

• Last four reported quarters (through Jun 30, 2026): revenue $98.9M, net income -$24.2M (-24.5% margin), free cash flow $105M (SEC filings).
• Insider open-market sales, last ~7 months: 13 Form 4 filings, $66.6M; 1 not under a Rule 10b5-1 plan ($63.5M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 1.90 on a 1–5 scale) (10 analysts), mean target USD 54.22 (range 48–62).
• Total return with dividends: 1Y +110.5% vs S&P 500 +14.4%; 5Y +111.4% vs S&P 500 +79.1%.
• Next earnings: 2026-11-09 (date not yet confirmed by the company), EPS estimate USD -0.4, revenue estimate $20.8M. All companies reporting that day: https://nexqual.com/earnings/2026-11-09
• Dividend: SEPN paid no cash dividend in the last five years.
• Short interest: 14.42% of float (as of 2026-10-15), 8.7 days to cover.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SEPN)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (SEPN)

P/S 21.4x · P/FCF 20.1x · P/B 5.5x · FCF yield 4.98% · Earnings yield -1.15%

Insider sales (SEC Form 4, open-market, last ~7 months) (SEPN)

12 of 13 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (SEPN)

Consensus Buy (mean 1.90 on a 1–5 scale), 10 analysts; mean target USD 54.22 (low 48, high 62).

Rating changes, last 120 days:

Total return (dividends reinvested) (SEPN)

Dividends (SEPN)

SEPN paid no cash dividend in the last five years.

Short interest (SEPN)

3,522,956 shares sold short, 14.42% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 2,894,002 shares (+21.7%). Days to cover: 8.7 (short shares ÷ average daily volume).

SEPN earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

SEPN recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

SEPN suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 9, 2026.

SEPN company outlook (results filed Aug 10, 2026)

• “SAD / MAD Data Expected in Q1 2027 Cash Position of $516.5 Million Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif. – August 10, 2026 – Septerna, Inc.”
• “Septerna expects its existing cash runway to fund operations at least into 2029. • Revenue: Revenue from the Novo Nordisk collaboration was $26.7 million for the quarter ended June 30, 2026, compared to $0.1 million from Vertex for the quarter ended June 30, 2025.”

Quoted word-for-word from the SEC 8-K results press release.

SEPN analyst estimates and revisions

SEPN options: expected move

Options price a move of about ±16.7% (±$7.35) by Nov 20, 2026, which includes earnings on Nov 9, 2026. Over the last 8 reports the stock moved ±6.5% on average.

30-day implied volatility 85.6% vs 51.1% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 22:13 UTC)

Technical Analysis (SEPN)

Nexqual's technical model rates SEPN "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 29, 2026 at 22:13 UTC.

Analyst Ratings (SEPN)

Wall Street analysts rate SEPN "Buy" based on 10 analysts, with a mean price target of USD 54.22 (range USD 48–62), per Nexqual as of October 29, 2026 at 22:13 UTC.

Earnings (SEPN)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 22:13 UTC.

Financials & Fundamentals (SEPN)

Source: Nexqual, October 29, 2026 at 22:13 UTC.

Financial Health Score (SEPN)

Nexqual rates Septerna, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 22:13 UTC.

Ownership (SEPN)

Source: Nexqual, October 29, 2026 at 22:13 UTC.

Leadership (SEPN)

Septerna, Inc. is led by Jeffrey T. Finer, Co-Founder, CEO & Director, per Nexqual as of October 29, 2026 at 22:13 UTC.

Major Backers & Investors (SEPN)

Notable institutional backers of Septerna, Inc. include Trv Gp V, LLC , RA Capital Management, L.P., Driehaus Capital Management, LLC, according to Nexqual as of October 29, 2026 at 22:13 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 22:13 UTC.

From Septerna, Inc.'s Latest SEC 10-K Filing (filed 2026-03-09)

Key Strengths & Strategy (as disclosed to the SEC)

• We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor ("GPCR") oral small molecule drug discovery powered by our proprietary Native Complex Platform®.
• Our proprietary Native Complex Platform® replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time.
• With our proprietary Native Complex Platform®, we can purify GPCRs outside of cells and reconstitute them into fully functional ternary complexes with transducer proteins (e.g., G proteins, beta-arrestins) and ligands (endogenous or synthetic), all housed within a well-defined lipid bilayer environment.
• Our oral small molecule drug discovery process, powered by our proprietary Native Complex Platform®, is depicted in the figure below.

Partnerships

• We plan to achieve this goal by efficiently advancing our portfolio of GPCR-targeted programs, continuing to expand our differentiated GPCR-targeted pipeline focused on indications with significant unmet needs, maximizing the potential of our Native Complex Platform® through continued innovation and investment, and evaluating potential value-creating strategic partnerships.
• After the Collaboration Agreement became effective on July 1, 2025, we and Novo commenced four simultaneous research and development programs (each an "R&D Program") with each pursuing one or more Collaboration Targets from discovery through development candidate selection.

Legal & Regulatory Risks (Item 1A, quoted)

• Our inability to complete development of, or commercialize our product candidates, or significant delays in doing so due to one or more of these factors, could have a material and adverse effect on our business, financial condition, results of operations and prospects.
• We may encounter substantial delays in the commencement, enrollment or completion of our planned clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, which could prevent us from commercializing any product candidates we determine to develop on a timely basis, if at all.
• We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs overseeing the conduct of such trials, by a Data Safety Monitoring Board for such trial or by the FDA, EMA, or other comparable foreign regulatory authorities.
• Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue from future product sales and regulatory and commercialization milestones.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 22:13 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt